Recent Finacing
Recent Raise
Salmedix in-licenses clinically characterized compounds and advances oncology programs (SDX-101, SDX-102, SDX-103), using tumor molecular testing and a network of drug hunters to identify likely responders.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
